Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity

A technology for lymphotoxin and chemotherapeutic drugs, which is applied in the application field of lymphotoxin in the preparation of drugs that increase the sensitivity of chemotherapeutic drugs, can solve the problems of large toxic and side effects, poor patient tolerance, etc., so as to improve the quality of life and reduce the toxic and side effects. Effect

Active Publication Date: 2007-11-21
上海复旦张江生物医药股份有限公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The purpose of the present invention is to provide a use of lymphotoxin, which is used as a sensitizer for tumor chemotherapy, so as to solve the shortcomings of current chemotherapy, such as large toxic side effects and poor patient tolerance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity
  • Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity
  • Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0246] Example 1. Chemosensitization effect of rhLT on BGC-823 (gastric cancer) cells

[0247] The experimental results are shown in Table 1. Carboplatin (CBDCA), cisplatin (CDDP), oxaliplatin (L-OHP), and doxorubicin (ADM) all showed synergistic effects in the 3 dose groups; 5-FU showed synergy in the high dose group and the middle dose group Synergistic effect; Mitomycin (MMC) only showed synergistic effect in the high-dose group; other drug groups had additive or sub-additive effects.

[0248] BGC-

Embodiment 2

[0249] Example 2. Chemosensitization effect of rhLT on NCI-H157 (non-small cell lung adenocarcinoma) cells

[0250] The experimental results are shown in Figure 1 and Table 2. Carboplatin (CBDCA), Cisplatin (CDDP), and Oxaliplatin (L-OHP) all showed synergistic effects in the three dose groups; Adriamycin (ADM) showed synergistic effects in the high-dose and intermediate-dose groups; others The drug group has superimposed or sub-superimposed effects.

[0251] NCI-

Embodiment 3

[0252] Example 3. Chemosensitization effect of rhLT on SW480 (colon cancer) cells

[0253] The experimental results are shown in Table 3. Carboplatin (CBDCA) and cisplatin (CDDP) showed a synergistic effect in the three dose groups; oxaliplatin (L-OHP) high-dose group and intermediate dose group showed a synergistic effect; adriamycin (ADM) showed a synergistic effect in high-dose groups. The group and the low-dose group showed synergistic effects; the other drug groups had additive effects.

[0254]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention concentrates on the protein engineering and the pharmacy domain, that is, the application of the lymphotoxin in the domanial of tumor therapy. It concerned with the purpose of one kind of lymphotoxin, as the sensitization agents of chemotherapy that it cures the epidermis source tumour. There is distinct cruative effect generated by applying lymphotoxin with chemotheraphy together, with platinum medicament especially. The advantages are: the application of the lymphotoxin with chemotheraphy improving the cruative effect or declines the chemotheraphy medicine dosage with permission of cruative effect gurantee, which it can reduces the nagtive side effect from chemotherapy and improves the life quality of the patient.

Description

Technical field [0001] The present invention relates to a new use of lymphotoxin, in particular to the use of lymphotoxin in the preparation of drugs that increase the sensitivity of chemotherapy drugs. Background technique [0002] Lymphotoxin a (LTα), also known as TNFβ, is a member of the TNF superfamily and is an important type of cytokine. LTα is produced by active lymphocytes and is a 25KD secreted glycoprotein. The LT precursor contains 205 amino acid residues, 34 of which encode the signal peptide, and the mature LT has 171 amino acid residues (18kD) ( SEQ ID NO: 3), without disulfide bond, position 62 is an N-linked glycosylation site (glycosylation is not necessary for its cytotoxic activity). The N-terminal 1-27 amino acid sequence of LT is a flexible structure, and the deletion of this region does not affect the binding of LT to the receptor and the cytotoxic activity induced. [0003] The structure and function of LTα are similar to TNF, and have the same receptors T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/19A61K45/06A61P35/00A61P43/00
Inventor 刘彦君沈毅君杨彤王婧吴劲松王征许燕王罗春
Owner 上海复旦张江生物医药股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap